Your SlideShare is downloading. ×
  • Like
  • Save
BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

BALKAN MCO 2011 - V. Gregorc - Epidemiology, pathology and molecular biology

  • 245 views
Published

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
245
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Colorectal cancer (CRC) epidemiology and pathology Gábor Cserni, MD, PhD, DSc Bács-Kiskun County Teaching Hospital Kecskemét, Hungary
  • 2. Incidence estimates ‘06
    • Europe
      • 217.4 thousand (men)
      • 195.4 thousand (women)
      • 412.9 thousand cases
      • approx. 12.9% of all cancer cases
    EUROPE EU Ann Oncol 2007;18:531
  • 3. Mortality ‘06
    • Europe
      • 107.6 thousand (men)
      • 99.9 thousand (women)
      • 207.4 thousand cases
      • approx. 12.2% of all cancer deaths
    EUROPE EU Ann Oncol 2007;18:531
  • 4. ACS 2010 n=72090 n=70480 Estimated deaths: 26580 Estimated deaths: 24790
  • 5. Risk factors
    • Age (>90% of CRC ≥ 50y)
    • Obesity
    • Inactivity
    • Diet (red and processed meat)
    • Heavy alcohol consumption
    • Long term smoking
    • ? Low fiber diet
    • Inflammatory bowel disease
    • Family history
    • Hereditary syndromes: FAP (APC), juvenile polyposis syndrome (SMAD4), HNPCC (MMR genes), Cowden sydrome (PTEN)
  • 6. Molecular pathways
    • Chromosome instability (85%)
      • Aneuploidy, gains and losses, translocations
    • Microsatellite instability (15%) – due to mismatch repair gene dysfunction
      • Mutation (if germline: HNPCC)
      • Methylation (sporadic MSI-H CRCs)
  • 7. Different pathways
    • Adenoma - carcinoma pathway
    • Serrated pathway
      • MSI-H - sessile serrated polyp/adenoma as precursor lesion (more often right sided)
      • Distal, MSI-L / MSS - traditional serrated adenoma (more often left sided)
  • 8. Based on: Jass JR. Histopathology 2007;50:113-130. MS: microsatellite; CIMP: CpG island methylator phenotype; TSA: traditional serrated adenoma Ex adenoma, TIL R>L F>M Neg MSI-H (HNPCC) Ex adenoma, dirty necrosis, tumor budding L>R M>F APC TP53 (KRAS) Neg MSS Ex villous adenoma (kras+) or serrated adenoma L>R M>F KRAS+ Low MSI- L or MSS Ex serrated polyps (TSA), serrated, mucinous, HG non-circumscribed, (TIL) R>L F>M BRAF+ High MSI- L or MSS Ex serrated polyps (sessile), serrated, mucinous , HG circumscribed, TIL R>L F>M BRAF+ High MSI-H (sporadic) Morphology Loc M / F Other CIMP MSI / MSS
  • 9. Phenotype of MSI-H tumors
    • Right / left colon (9:1)
    • More often exophytic
    • Mucinous type or component (>10%) or medullary type or component (>10%) or signet ring cell type or microglandular pattern
    • Tumor infiltrating lymphocytes ( TIL )
    • (minimum of 5 lymphocytes / 1 out 10 HPF)
  • 10. An example NOS Mucinous Signet ring cells MSH2 MLH1 TIL
  • 11. Histological types
    • Adenocarcinoma NOS (usual type)
      • dirty (intraglandular necrosis), CK20+, CK7-, cdx2+
    • Mucinous ( ≥ 50% component)
    • Signet ring cell ( ≥ 50% composed of such cells)
    • Medullary (no gland formation, tumor-infiltrating lymphocytes)
      • can be CK20- CK7- (or CK7+) cdx2+/- (or cdx2-)
    • Undifferentiated (no or at most 5% glands)
    • Other rare types: anenosquamous, squamous, WD or poorly differentiated neuroendocrine… etc
  • 12. Grade
    • For adenocarcinoma NOS
      • LG : >50% gland formation
      • HG : <50% gland formation
      • Three-tiered system: G1 - >95% gland forming & >75% of glands are smooth and regular & no significant component with high grade nuclei; G2 – 50-95% gland forming; G3 - <50% gland forming; ( G4 – undifferentiated tumours)
    • Signet ring cell carcinoma and small cell carcinoma are HG by definition
    • Medullary carcinoma should not be graded
    • Mucinous carcinomas : unsure whether they should be gr a ded or considered high grade.
  • 13. Medullary carcinoma MLH1 MSH2
  • 14. Prognostic factors (cat I – IIA)
    • Stage (pT, pN, M)
    • Lymphatic or venous invasion (L, V)
    • Completeness of excision with curative intent (R)
    • Grade
    • Type
    • Regression
    Based on Compton C et al. Arch Pathol Lab Med 2000
  • 15. Primary tumor: (c)T & pT ( TNM7 )
    • T & pT
      • TX: Not assessable (to be minimized)
      • T0 : No tumor
      • Tis : carcinoma in situ: intraepithelial tumor or involving the lamina propria ( intramucosal )
      • T1 : Tumor invading into submucosa .
      • T2 : Tumor invading into muscularis propria .
      • T3 : Tumor invading into pericolorectal tissues .
      • T4a: Tumor penetrating through visceral peritoneum.
      • T4b: Tumor invading into adjacent organs or structures (through the peritoneum or over the m. propria for retro- or infraperitoneal locali z ations)
  • 16. pT3: pT3a (up to 5 mm from the muscularis propria) & pT3b (over 5 mm from the muscularis propria)
    • pT3a tumors have a better prognostic profile than pT3b.
    Bori R et al. Pathol Oncol Res 2009;15:527-32.
  • 17. Assessment of peritoneal involvement Higher pT4 ration as a result of more precise pathological work-up
  • 18. Lymph nodes: pN
    • pNX : Not assessable (eg: removed earlier / not removed / no LNs identified)
    • pN0 : No regional LN metastasis (including isolated tumor cell clusters)
    • pN1 : Metastasis to 1-3 regional LNs
      • pN1mi Micrometastasis (>0.2 mm and/or >200 cells , but none > 2.0 mm)
      • pN1a Metastasis to 1 LN (>2 mm)
      • pN1b Metastasis to 2-3 LN (at least one metastasis >2 mm)
      • pN1c Tumor deposit(s) (TD) in the subserosa, mesocolon, pericolic, perirectal tissues, without LN structure, if there is no LN metastasis
    • pN2 : Metastasis to 4 or more regional LNs
      • pN2a Metastasis to 4-6 LNs (at least one metastasis >2 mm)
      • pN2b Metastasis to 7 or more LNs (at least one metastasis >2 mm)
  • 19. Lymph node metastasis vs TD
    • Tumor nodule lacking elements of a LN
    • TNM5
      • >3 mm: LN metastasis -> pN
      • ≤ 3 mm: discontinuous tumor spread -> pT
    • TNM6
      • Regular outline: LN metastasis -> pN
      • irregular outline: venous invasion: -> V1
  • 20. Lymph node metastasis vs TD V1 V1 – orcein stain
  • 21. Lymph node metastasis vs TD
    • Tumor nodule lacking elements of a LN
    • TNM7
      • Can be: discontinuous tumor spread, completely destroyed LN (N1/2), venous invasion (V1/2),
      • If destroyed LN: -> pN category
      • Discontinuous spread, venous invasion (V1/2) -> TD ( pN1c, if no LN metastasis, for T1-2 tumors)
    • TD and V1 on the basis of the orcein (elastica) stain
  • 22. The suggested number of LNs to be assessed for a reliable pN0
    • 6 Hernanz F et al. Dis Colon Rectum 1994;37:373-6.
    • 7 Caplin S et al. Cancer 1998;83:666-72. - Mainprize KS et al. J Clin Pathol 1998;51:165-6. - Cserni G. J Clin Pathol 2002;55:386-90.
    • 8 Maurel J et al. Cancer 1998;82:1482-6.
    • 9 Cianchi F et al. World J Surg 2002;26:384-9.
    • 12 TNM Supplement 3rd Ed
    • 13 Scott KWM et al. Br J Surg 1989;76:1165-7.
    • 14 Wong JH et al. J Clin Oncol 1999;17:2896-900. - Tepper JE et al. J Clin Oncol 2001;19:157-63.
    • 16 Cserni G et al. Pathol Oncol Res 1999;5:291-6.
    • 17 Goldstein NS. Am J Surg Pathol 2002;26:179-89.
    • 20 Greco P et al. Virchows Arch 2006;449:647-651.
  • 23. How many LNs? As many as possible ! 8574 T3N0M0 CRC from the SEER database Cserni G, et al . Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas? J Surg Oncol 2002; 81:63-69.
  • 24. Distribution of pN categories at BKMK
    • 1997
    • Mean (SD): 9,2 (6,1)
    • Median: 8
    • Range: 0-31
    • 2006
    • Mean (SD): 19 (11)
    • Median: 17
    • Range: 3-57
    Number of LNs assessed More
  • 25. Distance from the tumour as qualitative feature Cserni G, et al . Distance of lymph nodes from the tumor, an important feature in colorectal cancer specimens. Arch Pathol Lab Med 2001; 125:246-249. Tumour + 1-1 cm 2 cm 2 cm 3 cm 3 cm D C B A B C D 100 cases of CRC Mean: 17 LN / case
  • 26. An example A B A B B C C C No fraction D in this specific case
  • 27. Results
    • 53 pN1 or pN2
    • All but 1 staged correctly as pN+ on the basis of LNs from fraction A
    • All staged correctly on the basis of A and B (3 cms from the tumor in each direction
    • SUGGESTION:
    • LNs from below the tumor and its 3 cm-wide perimetry should be evaluated for reliable staging.
    • Look for further LNs if <7, or if pN1 with 3 LNs + !
    Cserni G, et al . Arch Pathol Lab Med 2001; 125:246-249.
  • 28. Further testing
    • 762 further CRCs studied - sections A & B (3cm) vs C & D (>3cm) till end 2008
    • Only 4/369 N+ cases had metastasis in a LN from segment CD without having metastasis in the AB segment.
    • 14 further cases would have been wrongly classified as pN1 instead of pN2
    • This error rate is LOWER than the FNR of lymphatic mapping
    Cserni G et al. J Clin Pathol 2011
  • 29. Sentinel nodes and lymphatic mapping in CRCs
    • 85/86 successfull SN identifications
    • 29 N+ cases ; 15 only SN+ (7 only micrometastatic; 2 only IHC)
    • 3 false negative cases
    • (3.6% FNR as reported - 10.3 % FNR as I understand it )
    • The aim would be a more reliable and improved staging (detailed pathology of SLNs).
    • Saha S et al. Ann Surg Oncol 2000;7:120-4 .
  • 30. Unexpected lymph drainage
    • Lymphatic mapping studies have demonstrated that direct drainage may occur from a tumor site to apical or even paraaortic LNs .
    • Merrie AE, et al. Dis Colon Rectum 2001; 44 :410-7.
    • T his LN proved to be the only positive LN resected with the colon, but was outside the margins of a standard right hemicolectomy , the operation usually performed for a primary carcinoma at the given location.
    • Ts i oulias GJ, et al. Arch Surg 2000; 135 :926-32.
    • Bilchik AJ, et al. J Clin Oncol 2001; 19 :1128-36.
    The only positive (only CK+) / 18 LN Same 2 cases reported in 2 papers
  • 31. Less success in other series (11-50 pts, mean 24 pts / series)
    • False negative rates (false negatives / all positives) & upstaging rates:
    • 1/3 (33%) & NA Evangelista W et al. Tumori 2002 ; 88 :37-40 .
    • 1/3 (33%) & 2/13 (15%) Tsoulias GJ et al. Am Surg 2002; 68 :561-5.
    • 5/13 (38%) & NA Cserni G et al. Pathol Oncol Res 1999; 5 :291-6.
    • 3/7 (43%) & 2/16 (13%) Merrie AE et al. Dis Colon Rectum 2001; 44 :410-7.
    • 2/7 (29%) & 2/20 (10%) F i tzg e rald TL et al. J Surg Oncol 2002; 80 :27-33.
    • 1/3 (33%) & NA Esser S et al. Dis Colon Rectum 2001; 44 :850-6
    • 2/8 (25%) & NA K i tagawa Y et al. Surg Clin North Am 2000; 80 :1799-809.
    • 12/20 (60%) & 2/15 (13%) Joosten JJA et al. Br J Surg 1999; 86 :482-6.
  • 32. Distant metastasis (M –pM)
    • cM0 N o distant metastasis .
    • M1/pM1 Distant metastasis.
      • - M1a: metastasis limited to one organ or localization (eg.: liver, lung, ovary, non regional LN…)
      • - M1b: multiple organs or localizations involved
  • 33. Venous invasion
    • HE detected VI in 18%
    • Orcein (elastica stain) detected VI in 71%
    • 11/89 CRCs had synchronous metastasis (M1)
      • 9 N+ (pN1 or pN2)
      • all VI+ i.e. V1
    • Median follow-up of 17 months 9 further cases were diagnosed with metachronous distant metastasis
      • 6 N+
      • and VI+
    • S pecificity and sensitivity for predicting distant metastasis :
      • LN metastasis : 0.56 and 0.75 , respectively
      • O rcein detected VI : 0.39 and 1 , respectively
    • Elastic stains enable the detection of clinically relevant VI in greater frequency than HE stained histological slides. If nodal involvement is an indication for systemic chemotherapy , our data suggest that VI detected by the orcein stain should also be an indication for that .
    Cserni G et al., JCP 2010;63(7):575-8.
  • 34. Suspected VI in muscularis pr NOT VI! Unsuspected VI in submucosa VI!
  • 35.  
  • 36. Resection margins
    • Longitudinal: rarely (1-2%) involved; to be assessed if <3 cm.
    • Circumferential (CRM) : involved in 5-36%; especially in rectum, whatever the mode of involvement
    Quirke P, Morris E. Histopathology 2007;50:103-12. Mucinous carcinoma CRM involvement: Local R1 resection (R2 if identified macroscopically
  • 37. Quality of surgery (TME)
    • Quirke's graded assessment of completeness of mesorectal excision (MRC trial) :
    • 3-Good: Intact mesorectum with only minor irregularities of a smooth mesorectal surface.  No defect is deeper then 5 mm.  No coning on the specimen.  Smooth CRM on slicing .
    • 2-Moderate: moderate bulk to the mesorectum but irregularity of the mesorectal su r face.   Moderate coning of the specimen towards the distal margin.  At no site is the m.propria visible with the exception of the insertion of levator muscles.  Moderate irregularity of CRM.
    • 1-Poor: Little bulk to mesorectum with defects down onto m.propria and/or very irregular cir c umferential resection margin.
  • 38.
    • Once the mesorectum has been violated the risk for spillage of tumor from lymphatics exists.   A ragged specimen without a smooth surface must therefore be a grade 2 .
  • 39. G 3 – Good quality - mesorectal plane (complete TME)
  • 40. G 1 – Poor quality - muscular plane (incomplete TME)
  • 41. Tumor regression grade (TRG)
    • Example ( Dworak 1997 )
    • A: G0 – no regression
    • B: G1 – dominant tumor with fibrosis
    • C: G2 – significant fibrosis with groups of tumor cells
    • D/E: G3 – dominant fibrosis or mucin with very few tumor cells
    • F: G4 – complete pathological regression
    Jacob C et al. J Pathol 2004;204:562-8.
  • 42. Predictive factors
    • MSI-H : better prognosis, but less effect expected from 5FU therapy ?
      • Ribic CM et al. NEJM 2003;349:247-57.
      • ? Meta-analysis of M1 CRC studies: no ( Des Guetz G et al. Eur J Cancer 2009;45:1890 )
      • As 5-FU mainly acts through the inhibition of TS…
    • Low tymidylate synthase ( TS ) expression in biopsy: predictive for response to neoadjuvant 5FU based chemoradiotherapy
    • Lower expression of TS and thymidine phosphorylase (TP) genes in post treatment tumor specimens of responders (vs non-responders).
      • Jacob C. J Pathol 2004;204:562-8.
  • 43. Predictive factors
    • K-RAS wild type (vs activating mutation) is predictive of response to anti-EGFR therpapies
    K-ras plays a central role in the downstream regulatory processes of the EGFR signaling pathway. Activating mutations abolish the GTP-ase activity required for inactivation.
  • 44. THE END